结肠镜与粪便免疫化学检测对比常规诊疗在结直肠癌诊断性筛查中的作用:SCREESCO随机对照试验
SCREESCO试验将278,280名60岁个体随机分配至一次性结肠镜组、2轮双粪便样本低阈值(10 μg g-1粪便)FIT组或常规诊疗对照组。中位随访4.8年后,结肠镜组结直肠癌发病率为每10万人年107.9例、对照组99.9例(IRR 1.08,95%CI 0.91-1.28),FIT组96.0例、对照组103.9例(IRR 0.92,95%CI 0.81-1.05)。结肠镜组Ⅰ-Ⅱ期结直肠癌检出率高于对照组(IRR 1.38,95%CI 1.09-1.74)。
要点
- 结肠镜筛查组结直肠癌总体发病率与对照组相比无显著差异,IRR为1.08(95%CI 0.91-1.28)。
- FIT筛查组结直肠癌总体发病率与对照组相比无显著差异,IRR为0.92(95%CI 0.81-1.05)。
- 干预组第一年心血管和胃肠道事件略高,随后与对照组更为接近。
核心结论
- 筛查使结直肠癌检出增加提示筛查获益,而不良事件增加提示存在一定初期危害。
研究设计与样本
- SCREESCO为随机对照试验,采用随机区组方法且未设盲,纳入278,280名60岁个体。
- 受试者按结肠镜与对照1:6、FIT与对照1:2的比例分配至一次性结肠镜、2轮双粪便样本FIT(阈值10 μg g-1粪便)或常规诊疗对照组。
- 分析中一次性结肠镜组31,113人、FIT组60,267人,结肠镜对照组186,671人,其中120,521人同时作为FIT组的对照。
主要发现
- 中位随访4.8年,结直肠癌发病率为结肠镜组每10万人年107.9例 vs 对照组99.9例(IRR 1.08,95%CI 0.91-1.28)。
- 结直肠癌发病率为FIT组每10万人年96.0例 vs 对照组103.9例(IRR 0.92,95%CI 0.81-1.05)。
- Ⅰ-Ⅱ期结直肠癌发生率高于对照组:结肠镜组IRR 1.38(95%CI 1.09-1.74),FIT组IRR 1.19(95%CI 0.99-1.43)。
- 干预组第一年心血管和胃肠道事件略高于对照组,随后与对照组更为接近。
关键数值与推荐
- 指南推荐50-75岁个体采用结肠镜或FIT筛查,许多筛查项目使用单样本每两年一次FIT。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a need to quantify the benefits and harms of colorectal cancer (CRC) screening using primary colonoscopy or fecal immunochemical testing (FIT) compared with usual care with no screening. Guidelines recommend screening in individuals aged 50-75 years using colonoscopy or FIT, and many screening programs use one-sample biennial FIT. Here we compare incidence of diagnosed CRCs and gastrointestinal and cardiovascular events between screening and usual care during the diagnostic phase of the SCREESCO trial. A randomized block method (no masking) assigned 278,280 individuals aged 60 years to once-only colonoscopy, 2 rounds of two-stool FIT with a low cutoff (10 μg g-1 feces) or usual care (control group) in a ratio of 1:6 for colonoscopy versus control and 1:2 for FIT versus control. In the analysis, 31,113 individuals were in the primary colonoscopy arm and 60,267 were in the FIT arm, and there were 186,671 primary colonoscopy controls, of whom 120,521 were also controls for comparison with the FIT arm. After a median follow-up of 4.8 years, the incidence rate of CRC was 107.9 in the colonoscopy arm and 99.9 in controls per 100,000 person-years (incidence rate ratio (IRR): 1.08, 95% confidence interval (CI): 0.91-1.28) and 96.0 in the FIT arm and 103.9 in controls (IRR: 0.92, 95% CI: 0.81-1.05). Rates of stage I-II CRC were higher in the colonoscopy arm (IRR: 1.38, 95% CI: 1.09-1.74) and in the FIT arm (IRR: 1.19, 95% CI: 0.99-1.43) versus controls. Rates of cardiovascular and gastrointestinal events were slightly higher in the intervention arms during the first year and were subsequently more similar to controls. Our findings of an increase in CRC detection implies a benefit of screening while the increase in adverse events suggests some initial harm. ClinicalTrials.gov: NCT02078804 .
引用
- Westerberg M, Ludvigsson JF, Metcalfe C, et al. Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial. Nat Med. 2026. PMID: 41721101. doi:10.1038/s41591-026-04225-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。